These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2856702)

  • 1. Specificity of the serotonergic antagonist ketanserin.
    Stott DJ; Robertson JI; Ball SG
    J Hypertens Suppl; 1985 Dec; 3(3):S191-3. PubMed ID: 2856702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketanserin: a possible tool for studying the role of serotonin in hypertension.
    Woittiez AJ; Wenting GJ; Man in't Veld AJ; Boomsma F; Schalekamp MA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S130-6. PubMed ID: 2412035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketanserin: systemic and regional hemodynamic characterization of its serotonergic and alpha-adrenergic receptor blocking effects in the pithed SHR.
    Scalbert E; Richer C; Giudicelli JF
    J Cardiovasc Pharmacol; 1989 Jan; 13(1):94-104. PubMed ID: 2468942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in vasodilating action between ketanserin, a 5-HT2-serotonergic receptor antagonist, and terazosin, an alpha 1-adrenoceptor antagonist, in anesthetized rabbits.
    Ikeda K; Takata M; Tomoda F; Mikawa M; Iida H; Sasayama S
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S69-72. PubMed ID: 2446076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the acute and chronic antihypertensive mechanism of action of ketanserin in spontaneously hypertensive rats.
    Balasubramaniam G; Lee HS; Mah SC
    J Pharmacol Exp Ther; 1993 Jan; 264(1):129-34. PubMed ID: 8093720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
    Hosie J; Stott DJ; Robertson JI; Ball SG
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S86-8. PubMed ID: 2446081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ketanserin on peripheral vascular pressor mechanisms in essential hypertension.
    Elliott HL; Donnelly R; Reid JL
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S62-6. PubMed ID: 2459518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketanserin: haemodynamic effects and mechanism of action.
    Schalekamp MA; Woittiez AJ; Wenting GJ; van den Meiracker AH; Man in 't Veld AJ
    J Hypertens Suppl; 1986 Apr; 4(1):S7-12. PubMed ID: 2871144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The alpha-adrenergic receptor blocking effect of ketanserin and the interaction between alpha-adrenergic and S2-serotonergic receptor blockade.
    van der Starre PJ; Reneman RS
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S54-61. PubMed ID: 2459516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in the chronic hypotensive mechanism of action of ketanserin in spontaneously hypertensive and Wistar-Kyoto rats.
    Balasubramaniam G; Lee HS; Mah SC
    J Hypertens; 1994 Jan; 12(1):7-14. PubMed ID: 8157947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal hemodynamic effects of ketanserin therapy in essential hypertension.
    Ram CV; Gonzalez DG; Kaplan NM; Ralakis JM; Henderson JD; Lugo CE; Zachariah N
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S78-80. PubMed ID: 2446078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential vascular alpha1-adrenoceptor blocking properties of an array of 5-HT receptor ligands in the rat.
    Centurión D; Mehotra S; Sánchez-López A; Gupta S; MaassenVanDenBrink A; Villalón CM
    Eur J Pharmacol; 2006 Mar; 535(1-3):234-42. PubMed ID: 16545797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients.
    Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vermylen J
    J Cardiovasc Pharmacol; 1984; 6(1):182-5. PubMed ID: 6199602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketanserin and alpha 1-adrenergic antagonism in humans.
    Zabludowski JR; Ball SG; Robertson JI
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S123-5. PubMed ID: 2412032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for an alpha-1 receptor-mediated central sympathoinhibitory action of ketanserin.
    McCall RB; Schuette MR
    J Pharmacol Exp Ther; 1984 Mar; 228(3):704-10. PubMed ID: 6323678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral and central cardiovascular effects of ketanserin in conscious normotensive rats.
    Davy M; Midol-Monnet M; Heimburger M; Beslot F; Cohen Y
    Arch Int Pharmacodyn Ther; 1987 Dec; 290(2):193-206. PubMed ID: 3128194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
    Andrén L; Svensson A; Dahlöf B; Eggertsen R; Hansson L
    Acta Med Scand; 1983; 214(2):125-30. PubMed ID: 6353879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive properties of ketanserin (R 41 468).
    Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
    Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonergic mechanisms and blood pressure in sheep.
    Nelson MA; Coghlan JP; Denton DA; Mills EH; Scoggins BA; Spence CD; Whitworth JA
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S117-9. PubMed ID: 2412029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketanserin-induced baroreflex enhancement in spontaneously hypertensive rats depends on central 5-HT(2A) receptors.
    Shen FM; Wang J; Ni CR; Yu JG; Wang WZ; Su DF
    Clin Exp Pharmacol Physiol; 2007 Aug; 34(8):702-7. PubMed ID: 17600544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.